

**This communication should be viewed by:**

Facility/Practice staff  
Clinical staff

## Pharmaceutical Policies Updates Effective April 1, 2023

MVP Health Care® (MVP) would like to make you aware of Pharmaceutical Policy updates effective April 1, 2023.

To view all current MVP Medical policies, *Sign In* at [mvphealthcare.com/providers](https://mvphealthcare.com/providers) and select *Resources*, then *Medical Policies*. All policies are reviewed at least once annually. This communication lists all impacted policies and their status. Policies fall into one of the following categories:

- **New** – Denotes a new policy
- **Updated** – Updated policies have content changes that may affect coverage criteria for services and/or drugs
- **Reviewed/No Changes**– Policies that have been reviewed but have no content change
- **Archived** – Denotes a policy that is no longer active

The following policies are effective April 1, 2023 and will be available for viewing on or before March 1, 2023. Hard copies of the policies are available upon request.

Pharmaceutical Policy Name	Status	Pharmaceutical Policy Name	Status
SGLT2 Inhibitors- Medicaid	Updated	Infertility Drug Therapy (Commercial/Marketplace)	Reviewed/No Changes
Growth Hormone Therapy	Updated	Infertility Drug Therapy (Medicaid/HARP)	Reviewed/No Changes
Disposable Insulin Delivery Devices – Medicaid	Updated	Jynarque	Reviewed/No Changes
Metformin ER	Updated	Transgender Hormone Therapy (Medicaid/HARP)	Reviewed/No Changes
Acthar	Updated	Transgender Hormone Therapy (COMM/EXCH/CHP)	Reviewed/No Changes
Select Injectables for Asthma	Updated	Male Hypogonadism	Reviewed/No Changes
Upadacitinib	Updated	Tepezza	Reviewed/No Changes
Teplizumab-mzww	New Policy	Physician Prescription Eligibility	Reviewed/No Changes
Phenylketonuria Agents	Reviewed/No Changes	Prescribers Treating Self or Family Members	Reviewed/No Changes
Zulresso (brexanolone)	Updated		

To view all communications, visit [mvphealthcare.com/FastFax](https://mvphealthcare.com/FastFax)

**Questions?** Contact your MVP Professional Relations Representative or call the MVP Customer Care Center for Provider Services at 1-800-684-9286.



## Effective February 1, 2023

Pharmaceutical Policy Name	Status
Adalimumab	Updated
Etanercept	Updated
Guselkumab	Updated
Infliximab	Updated
Risankizumab	Updated
Secukinumab	Updated
Ustekinumab	Updated
Apremilast	Updated
Abatacept	New Policy
Certolizumab	New Policy
Golimumab	New Policy
Tocilizumab	New Policy
Ganaxolone	New Policy

Pharmaceutical Policy Name	Status
Aduhelm (aducanumab-avwa) <b>Effective December 29, 2022</b>	Updated
Drug Utilization Review and Monitoring Program <b>Effective January 1, 2023</b>	Updated
Specialty Drug Procurement Exception (Commercial, Exchange & Select ASO business) <b>Effective January 1, 2023</b>	Updated

To receive future FastFax messages by email, send a request to [MVPFastFax@mvphealthcare.com](mailto:MVPFastFax@mvphealthcare.com).

**Questions?** Contact your MVP Professional Relations Representative or call the MVP Customer Care Center for Provider Services at 1-800-684-9286.

